San Diego, CA – January 20, 2023 – Mabwell Therapeutics, a U.S.-based biotechnology company and wholly owned subsidiary of Mabwell (Shanghai) Bioscience Co., Ltd. (688062.SH), announced today that it has entered into an exclusive licensing agreement with Disc Medicine, Inc. for the global development and commercialization of a portfolio of monoclonal antibodies targeting TMPRSS6 (Transmembrane Serine Protease 6). The portfolio includes MWTX-003, a clinical-stage candidate now ready for phase 1 trials.
MWTX-003 (also known as 9MW3011) is being developed to treat a range of hematologic disorders, including β-thalassemia and polycythemia vera by controlling iron homeostasis. Preclinical and clinical evidence has shown that reducing iron levels by inhibiting TMPRSS6 has potential to treat hematological diseases where iron dysregulation plays a central role. MWTX-003 is has received Investigational New Drug (IND) clearance from both the U.S. FDA (November 2022) and China’s NMPA (January 2023).
“We are thrilled to partner with Disc Medicine on the continued advancement of 9MW3011,” said Dr. Datao Liu, Co-founder and CEO of Mabwell. “Disc’s depth of expertise in hematologic disorders and iron biology makes them an ideal partner to accelerate global clinical development of this important therapeutic. This collaboration is a strong validation of Mabwell Therapeutics’ antibody discovery capabilities and supports our broader vision of addressing significant unmet needs in rare hematologic diseases.”
“Disc has built deep expertise in the role of iron homeostasis in hematologic disorders, and I am thrilled to expand our portfolio with these highly complementary antibody programs,” said John Quisel, J.D., Ph.D., Chief Executive Officer and President of Disc Medicine. “We are delighted to be partnering with Mabwell, a company with a strong antibody technology platform that is led by Dr. Xin Du, a leading expert on TMPRSS6 biology. This program is in perfect alignment with our strategy, and we look forward to advancing MWTX-003 into Phase 1 studies later this year.”
Under the terms of the agreement, Disc Medicine will receive exclusive rights to develop and commercialize MWTX-003 and other anti-TMPRSS6 monoclonal antibodies in the United States, Europe, and other territories outside of Greater China and Southeast Asia. Mabwell Therapeutics is eligible to receive up to $412.5 million in total payments, including a $10 million non-refundable upfront payment, development and commercial milestones, and tiered royalties approaching double digits on net sales of the licensed products.
About Mabwell Therapeutics
Mabwell Therapeutics is a U.S.-based biotechnology company focused on developing innovative antibody-based therapies for serious and rare diseases. It is a wholly owned subsidiary of Mabwell (Shanghai) Bioscience Co., Ltd. (688062.SH), a global integrated biopharmaceutical company primarily engaged in the discovery, development, manufacturing, and commercialization of biotherapeutics.
About Disc Medicine
Disc Medicine is a clinical-stage biopharmaceutical company committed to discovering, developing, and commercializing novel treatments for patients who suffer from serious hematologic diseases. Disc’s programs focus on key biological pathways underlying red blood cell biology, specifically heme biosynthesis and iron homeostasis. For more information, visit www.discmedicine.com.